サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1799106

喘息の世界市場

Asthma Disease

出版日
ページ情報
英文 177 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.56円
喘息の世界市場
出版日: 2025年08月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 177 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

喘息の世界市場は2030年までに392億米ドルに達する見込み

2024年に262億米ドルと推定される喘息の世界市場は、2024年から2030年にかけてCAGR 7.0％で成長し、2030年には392億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである小児科は、CAGR 8.3%を記録し、分析期間終了時には259億米ドルに達すると予測されます。成人セグメントの成長率は、分析期間中CAGR 4.6%と推定されます。

米国市場は71億米ドルと推定、中国はCAGR 11.2％で成長予測

米国の喘息市場は、2024年に71億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに83億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.2%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.8%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の喘息市場- 主要動向と促進要因のまとめ

喘息に対する世界の理解は、科学的進歩と疫学的動向によってどのように進展しているか？

気道の慢性炎症性疾患である喘息は、世界的に最も蔓延している複雑な呼吸器疾患の1つであり続け、あらゆる年齢、地域、社会経済的背景の人々に影響を及ぼしています。世界中で3億人以上が喘息とともに生活していると推定され、この疾患は公衆衛生上の大きな懸念となっています。近年の疫学と免疫学の進歩により、喘息は万能の疾患ではなく、複数の表現型とエンドタイプを持つ異質な疾患であるという理解が深まっています。この新たな理解は、喘息の診断と管理の方法を再構築し、個別化された治療戦略の必要性を浮き彫りにしています。遺伝的素因が主要な危険因子であることに変わりはないが、公害、アレルゲン、職業性刺激物質、都市化などの環境的影響が疾患の発症や増悪に関与している可能性が高まっています。特に低・中所得国における喘息有病率の増加は、ライフスタイルの変化、工業化の進展、診断不足を反映しています。喘息の負担は、喘鳴、息苦しさ、咳などの身体的症状にとどまらず、心理的苦痛、生活の質の低下、多大な経済的コストも含まれます。季節変動、呼吸器感染症、肥満やアレルギー性鼻炎などの併存疾患は、疾患管理をさらに複雑にしています。喘息の誘因、免疫経路、マイクロバイオームに関する研究の進展により、革新的な診断ツールや標的治療への道が開かれつつあります。喘息は管理可能な疾患であるにもかかわらず、治療へのアクセス格差、一貫性のない治療アドヒアランス、認識不足のために、予防可能な入院や死亡につながっています。この疾患に対する科学的洞察が深まるにつれて、喘息が世界的に及ぼす影響を効果的に軽減するためには、多因子にわたる、エビデンスに基づいた、個別化されたアプローチが必要であることがますます明らかになってきています。

どのような医療技術革新が喘息の診断と治療に変化をもたらしているのか？

喘息の管理は、早期診断、継続的モニタリング、的を絞った治療を強化する医療技術革新とデジタル技術の統合によって大きく進化しています。吸入コルチコステロイドと気管支拡張薬のみに頼る従来のアプローチは、生物学的製剤、精密医療、デジタルヘルスの進歩に牽引され、より洗練された治療パラダイムに変わりつつあります。IL-5、IL-4、IgEなどの特定の炎症経路を標的とするモノクローナル抗体などの生物学的製剤による治療は、従来の薬物療法に反応しない重症の好酸球性喘息やアレルギー性喘息患者の治療に革命をもたらしています。これらの標的療法は、増悪率を減少させ、肺機能を改善し、経口コルチコステロイド薬への依存を最小限にすることによって、治療成績を向上させています。診断面では、呼気一酸化窒素分画（FeNO）検査や血中好酸球数などのツールが、医師が喘息の表現型をより正確に分類し、それに応じて治療法を調整するのに役立っています。携帯型スパイロメトリー装置やデジタルピークフローメーターは、患者が自宅で肺機能をモニターすることを可能にし、自己管理と早期介入をサポートする貴重なリアルタイムデータを提供します。モバイルアプリやセンサー内蔵の吸入器の台頭により、服薬アドヒアランス、症状パターン、環境トリガーの追跡が可能になり、臨床医に実用的な洞察を提供しながら患者に力を与えることができます。人工知能は、過去のデータと実世界のエビデンスに基づいて増悪を予測し、治療計画をパーソナライズするために研究されています。モバイル機器と同期するスマート吸入器は、喘息ケアにおける最も一般的な課題の2つに対処することで、投与漏れや誤った吸入方法をユーザーに警告することができます。これらの技術革新は、より迅速で患者中心のケアモデルを構築し、日常的な治療と精密な喘息管理のギャップを埋めるのに役立っています。

社会経済的要因、ライフスタイルの変化、環境的プレッシャーは喘息の転帰にどのような影響を及ぼすか？

喘息の転帰は、集団や地域によって大きく異なる社会経済的決定要因、環境曝露、進化する生活習慣の複雑な相互作用に大きく影響されます。都市部では、交通排気ガス、産業廃棄物、建設粉塵などによる大気汚染への曝露が、特に小児や高齢者において、喘息の発症および増悪のリスクを著しく増大させる。副流煙、カビ、家庭内アレルゲンなどの要因に影響される室内空気の質も、特に住宅環境が劣悪な低所得者層では、重要な役割を果たしています。座りがちな生活習慣の増加や肥満率の上昇は、喘息コントロール不良の一因として浮上しており、代謝障害と気道炎症の亢進との関連を示す調査結果もあります。さらに、ヘルスケアへのアクセス、保険適用、ヘルスリテラシーの格差は、一貫性のない診断、治療開始の遅れ、最適とは言えない疾患コントロールの一因となっています。多くの新興諸国では、呼吸器専門医療の不在、安価な薬剤の不足、診断ツールの限られた利用可能性が効果的な管理を妨げ、救急受診や入院の割合の上昇につながっています。慢性疾患を取り巻く文化的な信念や偏見も、治療のアドヒアランスやケアを求める行動に影響を与える可能性があります。気候変動は、花粉の飛散時期の変化、山火事の頻度の増加、熱波の激化など、呼吸器症状を悪化させる可能性のある複雑な要素をさらに増やしています。さらに、ストレス、メンタルヘルスの問題、うつ病や不安症などの併存疾患は、喘息の症状を悪化させ、患者の転帰に悪影響を及ぼす要因として認識されつつあります。格差の是正と喘息治療の改善には、公共政策、教育、地域社会に根ざした介入を通じて、こうした広範な健康決定要因に対処することが世界的に不可欠です。

喘息Management市場の継続的な世界的成長の原動力は？

喘息管理市場の成長は、疾患有病率の上昇、認知度の向上、治療オプションの進歩、デジタルヘルスソリューションの利用拡大など、いくつかの集約的な要因によって牽引されています。世界の人口増加と都市化および公害の増加により、すべての年齢層で喘息の罹患率と診断率が上昇しています。社会的・臨床的意識の高まりにより、特に早期介入により疾患の進行を変えることができる小児集団において、より積極的なスクリーニングが行われるようになりました。医薬品の技術革新、特に生物学的製剤と併用吸入薬の分野では、治療手段が拡大し、より個別化された効果的な介入が可能となっています。価値観に基づくヘルスケアへのシフトは、予防、教育、アドヒアランスに焦点を当てた包括的な喘息管理プログラムの採用を促しています。政府や医療機関は、公衆衛生キャンペーン、学校ベースの啓発プログラム、喘息のコントロールと自己管理を強調するガイドラインに投資しています。先進的な治療法やデジタルツールの保険適用も広がっており、より幅広い患者層が利用できるようになっています。技術の進歩により、患者、医療提供者、支払者を連携したエコシステムにまとめる統合ケア・プラットフォームの開発が可能になっています。特にパンデミック後の遠隔診療の人気の高まりは、喘息に対する遠隔診療や在宅モニタリングソリューションの採用を加速させています。これと並行して、喘息の遺伝的・環境的基盤に関する調査から、より的確な予防戦略への道が開かれつつあります。これらの多様な促進要因が総体的に世界の喘息市場の持続的成長に寄与しており、この慢性呼吸器疾患患者の転帰と生活の質を改善するための継続的な技術革新と協力の必要性を浮き彫りにしています。

セグメント

年齢層（小児科、成人）

調査対象企業の例

  • AbbVie
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Circassia Pharmaceuticals
  • Cipla
  • GSK（GlaxoSmithKline）
  • Hikma Pharmaceuticals
  • Hyphens Pharma
  • Janssen Pharmaceuticals（J&J）
  • Mylan（now part of Viatris）
  • Novartis
  • Omega Pharma
  • Sanofi
  • Sandoz（Novartis）
  • Teva Pharmaceuticals
  • UCB
  • Vectura Group
  • Veracyte

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38502

Global Asthma Disease Market to Reach US$39.2 Billion by 2030

The global market for Asthma Disease estimated at US$26.2 Billion in the year 2024, is expected to reach US$39.2 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Pediatrics, one of the segments analyzed in the report, is expected to record a 8.3% CAGR and reach US$25.9 Billion by the end of the analysis period. Growth in the Adults segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$7.1 Billion While China is Forecast to Grow at 11.2% CAGR

The Asthma Disease market in the U.S. is estimated at US$7.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$8.3 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Asthma Disease Market - Key Trends & Drivers Summarized

How Is the Global Understanding of Asthma Evolving with Scientific Advances and Epidemiological Trends?

Asthma, a chronic inflammatory disease of the airways, continues to be one of the most prevalent and complex respiratory disorders globally, affecting people of all ages, geographies, and socioeconomic backgrounds. With over 300 million individuals estimated to be living with asthma worldwide, the condition represents a major public health concern. Recent advances in epidemiology and immunology have deepened the understanding of asthma as a heterogeneous disease with multiple phenotypes and endotypes, rather than a one-size-fits-all condition. This new understanding has reshaped the way asthma is diagnosed and managed, highlighting the need for personalized treatment strategies. While genetic predisposition remains a major risk factor, environmental influences such as pollution, allergens, occupational irritants, and urbanization are increasingly implicated in disease onset and exacerbation. The rise in asthma prevalence, particularly in low- and middle-income countries, reflects changing lifestyles, increased industrialization, and underdiagnosis. Asthma’s burden is not limited to physical symptoms such as wheezing, breathlessness, and coughing, but also includes psychological distress, reduced quality of life, and significant economic costs. Seasonal variations, respiratory infections, and comorbidities such as obesity and allergic rhinitis further complicate disease management. The growing body of research on asthma triggers, immune pathways, and the microbiome is paving the way for innovative diagnostic tools and targeted therapies. Despite being a manageable disease, asthma still leads to preventable hospitalizations and deaths due to disparities in access to care, inconsistent adherence to treatment, and lack of awareness. As scientific insight into the disease deepens, it is becoming increasingly clear that asthma requires a multifactorial, evidence-based, and individualized approach to effectively reduce its global impact.

What Medical and Technological Innovations Are Transforming Asthma Diagnosis and Treatment?

The management of asthma has evolved significantly with the integration of medical innovation and digital technologies that enhance early diagnosis, continuous monitoring, and targeted treatment. Traditional approaches that rely solely on inhaled corticosteroids and bronchodilators are giving way to more sophisticated treatment paradigms driven by advances in biologics, precision medicine, and digital health. Biologic therapies such as monoclonal antibodies targeting specific inflammatory pathways like IL-5, IL-4, and IgE are revolutionizing treatment for patients with severe, eosinophilic, or allergic asthma who do not respond well to conventional medications. These targeted therapies are improving outcomes by reducing exacerbation rates, improving lung function, and minimizing dependence on oral corticosteroids. On the diagnostic front, tools like fractional exhaled nitric oxide (FeNO) testing and blood eosinophil counts are helping physicians more accurately classify asthma phenotypes and adjust therapies accordingly. Portable spirometry devices and digital peak flow meters allow patients to monitor lung function at home, providing valuable real-time data that supports self-management and early intervention. The rise of mobile apps and connected inhalers with embedded sensors enables tracking of medication adherence, symptom patterns, and environmental triggers, empowering patients while providing clinicians with actionable insights. Artificial intelligence is being explored to predict exacerbations and personalize treatment plans based on historical data and real-world evidence. Smart inhalers that sync with mobile devices can alert users to missed doses or incorrect inhaler techniques, addressing two of the most common challenges in asthma care. These innovations are creating a more responsive and patient-centered care model, helping to bridge the gap between routine treatment and precision-based asthma management.

How Do Socioeconomic Factors, Lifestyle Changes, and Environmental Pressures Impact Asthma Outcomes?

Asthma outcomes are profoundly influenced by a complex interplay of socioeconomic determinants, environmental exposures, and evolving lifestyle habits that vary widely across populations and regions. In urban areas, exposure to air pollution from traffic emissions, industrial waste, and construction dust significantly increases the risk of asthma onset and exacerbation, particularly in children and the elderly. Indoor air quality, influenced by factors such as secondhand smoke, mold, and household allergens, also plays a critical role, especially in low-income settings where housing conditions may be poor. The increasing adoption of sedentary lifestyles and rising rates of obesity are emerging as contributors to poor asthma control, with research indicating a link between metabolic disorders and heightened airway inflammation. In addition, disparities in healthcare access, insurance coverage, and health literacy contribute to inconsistent diagnosis, delayed treatment initiation, and suboptimal disease control. In many developing countries, the absence of specialized respiratory care, lack of affordable medications, and limited availability of diagnostic tools hinder effective management, leading to higher rates of emergency visits and hospitalizations. Cultural beliefs and stigma surrounding chronic illnesses may also affect treatment adherence and care-seeking behavior. Climate change is adding another layer of complexity by altering pollen seasons, increasing the frequency of wildfires, and intensifying heat waves, all of which can worsen respiratory symptoms. Moreover, stress, mental health issues, and comorbid conditions such as depression and anxiety are increasingly recognized as factors that exacerbate asthma symptoms and negatively impact patient outcomes. Addressing these broader determinants of health through public policy, education, and community-based interventions is essential to reducing disparities and improving asthma care globally.

What Is Driving the Continued Global Growth of the Asthma Disease Management Market?

The growth in the asthma disease management market is driven by several converging factors, including rising disease prevalence, increasing awareness, advances in therapeutic options, and expanding use of digital health solutions. A growing global population, coupled with increased urbanization and pollution, has led to higher incidence and diagnosis rates of asthma across all age groups. Heightened public and clinical awareness has resulted in more proactive screening, especially in pediatric populations where early intervention can alter disease progression. Pharmaceutical innovations, particularly in the area of biologics and combination inhalers, are expanding the treatment arsenal, allowing for more tailored and effective interventions. The shift toward value-based healthcare is encouraging the adoption of comprehensive asthma management programs that focus on prevention, education, and adherence. Governments and health organizations are investing in public health campaigns, school-based awareness programs, and guidelines that emphasize asthma control and self-management. Insurance coverage for advanced therapies and digital tools is also becoming more widespread, making them accessible to a broader patient population. Technological advancements are enabling the development of integrated care platforms that bring together patients, providers, and payers in a coordinated ecosystem. The increasing popularity of remote care, especially post-pandemic, has accelerated the adoption of telemedicine and home-monitoring solutions for asthma. In parallel, research into the genetic and environmental underpinnings of asthma continues to yield insights that could pave the way for even more precise and preventive strategies. These diverse drivers are collectively contributing to sustained growth in the global asthma market, highlighting the need for ongoing innovation and collaboration to improve outcomes and quality of life for individuals living with this chronic respiratory condition.

SCOPE OF STUDY:

The report analyzes the Asthma Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Age Group (Pediatrics, Adults)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Circassia Pharmaceuticals
  • Cipla
  • GSK (GlaxoSmithKline)
  • Hikma Pharmaceuticals
  • Hyphens Pharma
  • Janssen Pharmaceuticals (J&J)
  • Mylan (now part of Viatris)
  • Novartis
  • Omega Pharma
  • Sanofi
  • Sandoz (Novartis)
  • Teva Pharmaceuticals
  • UCB
  • Vectura Group
  • Veracyte

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Asthma Disease - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Prevalence of Asthma Spurs Sustained Demand for Long-Term Maintenance and Rescue Therapies
    • Here's How Urbanization, Pollution, and Climate Change Strengthen the Case for Expanded Asthma Diagnosis and Treatment Programs
    • Increased Focus on Early Detection and Prevention Throws the Spotlight on Biomarker-Based and Digital Screening Tools
    • Growing Awareness and Patient Education Initiatives Drive Higher Diagnosis Rates and Treatment Adherence
    • Here's the Story: Advances in Biologic Therapies Transform Management of Severe and Eosinophilic Asthma Subtypes
    • Development of Personalized Treatment Protocols Expands the Addressable Market for Genotype and Phenotype-Driven Asthma Care
    • Integration of Smart Inhalers and Digital Health Platforms Enables Remote Monitoring and Data-Driven Intervention
    • Expansion of Asthma Management Guidelines in Emerging Economies Fuels Growth in Inhaled Corticosteroids and Combination Inhalers
    • Here's the Story: AI and Predictive Analytics Enhance Risk Stratification and Exacerbation Forecasting in Chronic Asthma Patients
    • Pediatric and Geriatric Population Growth Supports Long-Term Market Opportunities Across Age Groups
    • Environmental Allergen Sensitization and Indoor Air Quality Issues Drive Demand for Comprehensive Management Approaches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Asthma Disease Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Asthma Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Pediatrics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Pediatrics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Adults by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Adults by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 11: USA Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: USA Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: USA 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 14: Canada Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 15: Canada Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: Canada 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • JAPAN
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 17: Japan Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 18: Japan Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: Japan 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • CHINA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 20: China Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: China Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: China 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • EUROPE
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 23: Europe Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: Europe Historic Review for Asthma Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: Europe 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • FRANCE
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 29: France Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: France Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: France 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • GERMANY
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 32: Germany Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Germany Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: Germany 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 35: Italy Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Italy Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Italy 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 38: UK Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: UK Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: UK 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 41: Spain Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Spain Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Spain 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 44: Russia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Russia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Russia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 47: Rest of Europe Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Rest of Europe Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: Rest of Europe 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 50: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Asia-Pacific Historic Review for Asthma Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: Asia-Pacific 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 56: Australia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Australia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Australia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • INDIA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 59: India Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: India Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: India 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 62: South Korea Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: South Korea Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: South Korea 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 65: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Rest of Asia-Pacific Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: Rest of Asia-Pacific 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 68: Latin America Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 69: Latin America Historic Review for Asthma Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Latin America 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 74: Argentina Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Argentina Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Argentina 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 77: Brazil Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Brazil Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Brazil 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 80: Mexico Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Mexico Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: Mexico 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 83: Rest of Latin America Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Latin America Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: Rest of Latin America 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 86: Middle East Recent Past, Current & Future Analysis for Asthma Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 87: Middle East Historic Review for Asthma Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Middle East 16-Year Perspective for Asthma Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 92: Iran Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Iran Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Iran 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 95: Israel Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Israel Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Israel 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 98: Saudi Arabia Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Saudi Arabia Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Saudi Arabia 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 101: UAE Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UAE Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: UAE 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 104: Rest of Middle East Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Middle East Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Rest of Middle East 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030
  • AFRICA
    • Asthma Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 107: Africa Recent Past, Current & Future Analysis for Asthma Disease by Age Group - Pediatrics and Adults - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Africa Historic Review for Asthma Disease by Age Group - Pediatrics and Adults Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Africa 16-Year Perspective for Asthma Disease by Age Group - Percentage Breakdown of Value Sales for Pediatrics and Adults for the Years 2014, 2025 & 2030

IV. COMPETITION